AVANT Immunotherapeutics Inc. (Nasdaq: AVAN) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : AVANT Immunotherapeutics Inc. (Nasdaq: AVAN)

AVAN 10.04

0.0%

Jun 12 9:41 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Salt'n'Peppa who wrote (302)	3/12/2000 1:13:00 AM
From: RWReeves	Read Replies (2) of 513

AVAN pipeline 10kwizard.com This will help break the code: under development: TP10 - soluble form of complement receptor 1 - sCR1 in Phase IIa trials for ARDS, Phase I/II trials on reperfusion injury after lung transplant and Phase I trials for Myocardial Infarction. In preclinical studies re: organ transplantation and autoimmune disease applications. (SB)(CIP) - small molecule compounds - TAQ-588 a T cell activation inhibitor re: transplant rejection, autoimmune diseases and a therapeutic atherosclerosis vaccine. - under development: TCAR - T Cell Antigen Receptor Program - under development: sCRlsLex - targeted complement inhibitor and cell adhesion inhibitor re: inflammatory and cardiovascular disease - under development: TM27 - T cell receptor MAb re: multiple sclerosis (Astra AB collaboration) - under development: TP12 - T cell receptor vaccine re: multiple sclerosis (Astra AB collaboration) - under development: TAO 588 - long term immunosuppression - organ transplant rejection, autoimmune diseases in preclinicals - under development: T cell suppressors and activators - synthetic chemical library screening (ArQule collaboration) - under development: small molecule immunoregulatory compounds - natural products library screening (MYCOsearch collaboration) - under development: anti-CETP Vaccine re: atherosclerosis prevention - lowering cholesterol in preclinicals Currently a discussion of TCEL's complement program on the GLIA thread (anyway, I am discussing it over there) in relation to GLIA and ALXN. Message 13183794 Anyone with better memory current information would be welcome to jump in. Heck of an IP portfolio, which attracted me in the first place. RWR

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next